Drugs /

cd30 car-expressing autologous t lymphocytes

Back to Drugs List

Overview

NCI Definition [1]:
A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the CD30 antigen, with potential immunostimulating and antineoplastic activities. Upon administration, the CD30 CAR-expressing autologous T-lymphocytes specifically recognize and bind to CD30-expressing tumor cells, resulting in tumor cell lysis. CD30, a cell surface receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is transiently expressed on activated lymphocytes and is constitutively expressed in hematologic malignancies.

Clinical Trials

View Clinical Trials for cd30 car-expressing autologous t lymphocytes

Cd30 car-expressing autologous t lymphocytes has been investigated in 7 clinical trials, of which 7 are open and 0 are closed. Of the trials investigating cd30 car-expressing autologous t lymphocytes, 4 are phase 1 (4 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open).

TNFRSF8 Expression is the most frequent biomarker inclusion criterion for cd30 car-expressing autologous t lymphocytes clinical trials.

Anaplastic large cell lymphoma, hodgkin lymphoma, and non-hodgkin lymphoma are the most common diseases being investigated in cd30 car-expressing autologous t lymphocytes clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Cd30 Car-Expressing Autologous T Lymphocytes
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating cd30 car-expressing autologous t lymphocytes and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
car.cd30-expressing autologous t lymphocytes, anti-cd30 car-expressing autologous t lymphocytes
Drug Target(s) [2]:
TNFRSF8
NCIT ID [1]:
C116738

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.